Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03399461 · ClinicalTrials.gov registry record
Targeted Literature Review and Subject Interviews in Wiskott-Aldrich Syndrome (WAS)
A clinical trial, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- 19
- Enrollment target
NCT03399461: Completed study, sponsored by GlaxoSmithKline.
NCT03399461 is a clinical trial that has completed, run by GlaxoSmithKline. The registered enrollment target is 19 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03399461 has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- 19 participants
- Enrollment target
Study Summary
WAS is a rare primary immune deficiency disease caused by genetic mutation and is more common in males than females. The purpose of this study is to understand experiences of WAS subjects and caregivers to identify important concepts of interest that could be measured in future Phase IIIb trials. This is a qualitative cross-sectional study that will include a sample of approximately, 8 subjects with WAS and 13 caregivers of subjects with a diagnosis of WAS in the United States, United Kingdom and France. A 60 to 90 minute open-ended interview will be conducted over the telephone or video conference that will be audio-recorded for subsequent transcription. The aim of these interviews is to obtain subject and caregiver perspectives on the impact of WAS and its associated treatments on quality of life and experiences of living with WAS.
Primary Outcome
Open-ended interviews will be conducted in adolescent and adult subjects to understand their perspective on WAS.
Interventions
- OTHER Sociodemographic questionnaire
- OTHER Patient Interview guide
- OTHER Caregiver interview guide
- OTHER Pediatric quality of life (PedsQL) questionnaire
- OTHER Clinical questionnaire
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2018-01-24 |
| Est. Completion | 2018-09-14 |
What the finished NCT03399461 record still lists
NCT03399461 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 19 participants, a relatively small participant target.
The record links to 0 conditions, and to 5 interventions - of which Sociodemographic questionnaire is the first listed.
NCT03399461 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03399461 about?
NCT03399461 is a clinical study titled "Targeted Literature Review and Subject Interviews in Wiskott-Aldrich Syndrome (WAS)". WAS is a rare primary immune deficiency disease caused by genetic mutation and is more common in males than females. The purpose of this study is to understand experiences of WAS subjects and caregivers to identify important concepts of interest that could be measured in future Phase IIIb trials. Th...
What is the current status of trial NCT03399461?
This trial is currently completed. The enrollment target is 19 participants. The study started on 2018-01-24. Estimated completion is 2018-09-14.
What interventions are being tested in trial NCT03399461?
The interventions under investigation include: Sociodemographic questionnaire (OTHER), Patient Interview guide (OTHER), Caregiver interview guide (OTHER), Pediatric quality of life (PedsQL) questionnaire (OTHER), Clinical questionnaire (OTHER).
Who is sponsoring clinical trial NCT03399461?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI